Sionna Therapeutics, Inc. (SION) Stock Price & How to Invest

Sionna Therapeutics (Nasdaq: SION) is a clinical-stage biopharmaceutical company focused on cystic fibrosis (CF). Its candidates are first-in-class stabilizers of the nucleotide-binding domain 1 (NBD1) of the CFTR protein, the region disrupted by the F508del mutation that affects roughly 90% of CF patients. The original thesis was that stabilizing NBD1 could restore CFTR function toward wild-type levels and, added on top of the current standard of care (Vertex's Trikafta), deliver clinically meaningful improvement. The company went public in February 2025 at $18.00 per share, raising about $219 million in an upsized IPO.

That add-on thesis did not hold up. In August 2026 the PreciSION CF Phase 2a trial of SION-719, in 15 adults homozygous for F508del who were already on Trikafta, missed its key activity endpoint: the placebo-adjusted change in sweat chloride was about -1.0 mmol/L in the primary analysis. Sionna said Trikafta exposure dropped about 25-30% while patients took SION-719, and preclinical work suggests an NBD1 stabilizer and a potentiator may interact to blunt benefit. It ended SION-719 as an add-on. In September it announced a ~46% workforce reduction (about $6.4 million of restructuring charges) and a new plan: switch patients off Trikafta onto a dual combination of SION-451 and SION-2222 in an open-label Phase 2a proof-of-concept trial called AscenSION CF, expected to start in Q1 2027. Phase 1 healthy-volunteer data for that combination met its safety, tolerability and pharmacokinetic objectives.

Financially, Sionna has no product sales. It lost about $75 million in 2025 and about $57 million in the first half of 2026 (~$27 million in Q1 and ~$30 million in Q2), and held about $268 million of cash, equivalents and marketable securities at June 30, 2026, which management now expects to last into the second half of 2029. The stock closed near $3.81 on October 16, 2026, down ~90% year to date and ~88% over one year, for a market capitalization near ~$172 million. That is below the cash on hand, so the market is assigning little or negative value to the remaining pipeline.

As a pre-revenue clinical-stage biotech that has already had one major trial failure, Sionna faces the standard binary risk that the next trial disappoints as well. The NBD1 mechanism has not yet shown a clear benefit in CF patients, and the new combination must compete directly with Vertex's highly effective modulators rather than add to them. The next meaningful clinical data are well over a year away, since the AscenSION CF trial is not expected to start until Q1 2027, so the stock may drift without catalysts while cash is consumed. Quarterly losses were still about $30 million in Q2 2026 before the restructuring took effect. Further setbacks could lead to another restructuring, a strategic sale or a wind-down, and any eventual approval path would likely need more financing and dilution. Analyst sentiment has turned cautious (a Hold average across ~7 analysts), and regulatory, manufacturing and enrollment delays could each push timelines out further.

7 analysts publish price targets on SION, averaging $21.00 against a $3.89 price as of October 2026, or +439.8%. The published targets run from $5.00 to $63.00, a wide spread, and the ratings split 2 buy, 10 hold, 0 sell. Over the last six months there have been 4 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full SION forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Sionna Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The SION-451 + SION-2222 combination. With SION-719 stopped as an add-on, the investment case now rests on the dual combination of SION-451 (dosed twice daily) and SION-2222 (once daily). The most optimistic published target, $63.00, assumes this works close to its best case.

The case against. As a pre-revenue clinical-stage biotech that has already had one major trial failure, Sionna faces the standard binary risk that the next trial disappoints as well. The most pessimistic target, $5.00, is roughly what SION is worth if this bites instead.

Read the full bull and bear case on SION, including what would have to change to break either one. Walnut is not an investment adviser.

No. Sionna Therapeutics, Inc. (SION) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Sionna Therapeutics, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$0 (no approved product)
• Net loss (TTM): ~$97M (Q2 2026 ~$30M; FY2025 ~$75M)
• EPS (Q2 2026): ~-$0.66 vs ~-$0.65 expected
• Cash & marketable securities: ~$268M at June 30, 2026 (runway into 2H 2029)
• Market cap: ~$172M (share price ~$3.81 on October 16, 2026)
• Price-to-book: ~0.65x
• Restructuring: ~46% workforce cut, ~$6.4M of charges

SION has no product revenue and runs steady operating losses, which is normal for a clinical-stage biotech funding trials, so traditional earnings multiples do not apply. After the SION-719 failure the stock trades at roughly 0.65x book value, with a market cap of about $172 million against roughly $211-268 million of cash depending on the measure, which means the market is pricing the remaining pipeline at little or below zero. The next earnings report is expected around November 5, 2026 (an estimated date), with consensus calling for a loss of about $0.68 per share.

Other names that sit close to SION: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get SION exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so SION sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where SION fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

SION is a pre-revenue cystic fibrosis biotech that lost its lead program in 2026 and now trades at a market value (~$172 million) below its cash, so its value hinges on whether the SION-451 + SION-2222 combination can show a benefit in a trial that does not start until early 2027, and on how carefully management spends the cash in the meantime.

Whether SION is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SION a buy or a sell?, and where the stock could go from here in the SION stock forecast.

For income investors, whether SION pays a dividend and how the payout looks is covered in does SION pay a dividend? And to weigh SION against a peer, read the full side-by-side comparisons: SION vs CF and SION vs VRTX.